VPC
DFTX

Vestal Point Capital’s Definium Therapeutics DFTX Stock Holding History

Vestal Point Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-637,000
Closed -$8.53M – 105
2025
Q4 		$8.53M Buy
+637,000
New +$7.88M 0.29% 52

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vestal Point Capital's DFTX Position: Q1 2026 in Review

Vestal Point Capital sold out of Definium Therapeutics (DFTX) in Q1 2026, closing a stake of 637,000 shares — an estimated $8.53M sold.

Vestal Point Capital first reported a position in DFTX in Q4 2025 and held it in 1 quarter. The position peaked at $8.53M in Q4 2025. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Vestal Point Capital reported no remaining Definium Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vestal Point Capital sold 637,000 Definium Therapeutics shares in Q1 2026, an estimated $8.53M.
  • Vestal Point Capital first reported a position in Definium Therapeutics in Q4 2025 and held it in 1 quarter.
  • Vestal Point Capital's Definium Therapeutics position peaked at $8.53M in Q4 2025.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.